Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
A condensed course of post-prostatectomy radiation holds its own against the standard regimen at 5 years, but comes with a notable trade-off. Phase 3 trial NRG-GU003 found hypofractionated RT (HYPORT) was noninferior for patient-reported urinary and bowel outcomes, yet physician-reported grade 3 genitourinary toxicity was twice as high — 16% vs. 7%. The shorter schedule cuts treatment visits by a third, but the GU risk warrants careful shared decision-making.
A shorter course of post-prostatectomy radiotherapy is just as effective as the conventional approach at 5 years — but it doesn't come without strings attached. Results from the phase 3 NRG-GU003 trial, presented at ASTRO 2026, confirmed that hypofractionated postprostatectomy radiotherapy (HYPORT) remains noninferior to conventionally fractionated RT (COPORT) for patient-reported urinary and bowel outcomes. Disease control was also comparable, with progression rates of ~25% vs. ~22%.
The catch? Physician-reported grade 3 genitourinary (GU) toxicity was significantly higher with HYPORT, driven largely by noninfective cystitis and hematuria. While patients themselves didn't report worse outcomes, clinicians flagged meaningful adverse events that experts say shouldn't be dismissed. Discussant Dr. Sophia Kamran noted that HYPORT may be best suited for older patients or those facing logistical or financial barriers to longer treatment — and cautioned that 5 years may not fully capture late toxicity risk.
By the Numbers:
Why it matters: HYPORT offers a real convenience win — fewer clinic visits, lower burden — but the elevated GU toxicity signal means it's not a one-size-fits-all swap. Clinicians need to weigh patient age, risk tolerance, and logistics carefully before recommending the shorter regimen.
